Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | CDK9 | P50750 | 4/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 4/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666739 | 0.81 | BRD4 (1.00) | BRD4DYRK1ARETKDRFLT3 | |
| SCHEMBL30663475 | 0.81 | BRD4 (1.00) | BRD4DYRK1ARETKDRFLT3 | |
| SCHEMBL13302165 | 0.77 | DYRK1A (0.56) | BRD4DYRK1ARETFLT3CCNB2 | |
| SCHEMBL857542 | 0.76 | BRD4 (0.64) | BRD4DYRK1ARETKDRFLT3 | |
| SCHEMBL3333307 | 0.74 | CDC7 (0.52) | DYRK1ARETFLT3CCNB2CDK1 | |
| SCHEMBL20293060 | 0.74 | DYRK1A (1.00) | BRD4DYRK1ARETKDRFLT3 | |
| SCHEMBL3773981 | 0.74 | RET (1.00) | BRD4RETCCNB2CDK1CCNB1 | |
| SCHEMBL29428421 | 0.73 | MAPT (0.51) | — | |
| SCHEMBL2698582 | 0.73 | MAPT (0.51) | — | |
| SCHEMBL857208 | 0.73 | BRD4 (0.76) | BRD4DYRK1AKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | BRD4 521/4885DYRK1A 2055/4885RET 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.